CC-115

Phase 2Small molecule

Bristol-Myers Squibb

CC-115 is one of 111 small molecule programs targeting Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

Prostate CancerActive, not recruiting

GlioblastomaActive, not recruiting

Multiple MyelomaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

Prostate CancerPhase 1

Active, not recruiting

GlioblastomaPhase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

CC-115

Bristol-Myers Squibb

Phase 2

3 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Velban

EEastern Cooperative Oncology Group

Preclinical

15 4

Zofran

Novartis

Preclinical

2 5

Norvir

AbbVie

Preclinical

1 6

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 7

Tafasitamab

Incyte

Preclinical

7 8

Nuvigil

NNuvo Research GmbH

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Recruiting

Glioblastoma

NCT02977780

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01353625·118 enrolled

Prostate Cancer1 trial

Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02833883·40 enrolled

Glioblastoma1 trial

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Recruiting·PPatrick Wen, MD·Phase 2·NCT02977780·460 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CC-115. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CC-115 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CC-115. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

CC-115

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors1 trial

Prostate Cancer1 trial

Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News